novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
Published 6 years ago • 350 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
1:32
novel agent combinations: the future of cll
-
6:43
key highlights in cll: clinical trial updates & the role of combination therapies and novel btkis
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:25
novel revelations in cll biology with venetoclax/ibrutinib
-
2:01
novel combination therapies for the treatment of cll
-
3:13
cll versus other leukemia types
-
4:20
stories of transformation - marianne
-
3:30
significance of watch-and-wait approach in cll
-
1:22
novel agents in cll: acalabrutinib and zanubrutinib
-
1:09
novel ventoclax combinations for cll
-
2:04
how do we sequence and combine novel agent-based therapies in cll?
-
3:29
novel venetoclax combination therapy advancing the field of cll
-
1:44
novel combination therapies in cll
-
1:01
cll resistance mechanisms in the era of novel agents
-
1:09
cll treatment: novel agents vs. cellular therapies
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
2:36
novel non-immunological agents currently under investigation for cll
-
2:37
allo-hsct for cll in the era of novel agents
-
1:31
novel approaches to cll treatment
-
2:09
novel agents in cll: could they make chemotherapy redundant?
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
2:14
novel approaches to first line cll treatment